---
schema_version: "secwatch.filing_event.v1"
accession: "0001720580-26-000036"
form_type: "8-K"
ticker: "ACET"
cik: "0001720580"
company_name: "Adicet Bio, Inc."
filed_at: "2026-05-13T20:04:12+00:00"
generated_at: "2026-05-13T22:15:21.578271+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Adicet Bio Q1 net loss $20.2M; prula-cel Phase 1 data expected mid-2026

## Summary
- Net loss $20.2M ($1.88/share) vs $28.2M ($4.96/share) in Q1 2025; R&D expenses down to $17.5M.
- Cash, cash equivalents and ST investments $137.6M at March 31, 2026; expected runway into H2 2027.
- Phase 1 prula-cel update in mid-2026 with at least 20 LN/SLE patients, min 6 months follow-up.
- FDA interaction in Q2 2026 to inform potential pivotal trial design; plan to start pivotal program in H2 2026.
- Regulatory filing for ADI-212 in mCRPC planned for Q3 2026; Phase 1 enrollment expected Q4 2026.

## SEC filing metadata
- accession: 0001720580-26-000036
- form_type: 8-K
- ticker: ACET
- cik: 0001720580
- company_name: Adicet Bio, Inc.
- filed_at: 2026-05-13T20:04:12+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1720580/000172058026000036/0001720580-26-000036-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1720580/000172058026000036/acet-20260513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001720580-26-000036
- JSON: https://secwatch.observer/filing/0001720580-26-000036.json
- Plain text: https://secwatch.observer/filing/0001720580-26-000036.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.